Russian journal of anaesthesiology and reanimatology 2, 2019 Клинические рекомендации фар
жүктеу/скачать 0,76 Mb. Pdf көрінісі
|
Anestesiolog 2019 02 005
Оқулық Клиникаға кіріспе, 32, 34 тарих, Skleroz 2012 Nv9 005, Otorino 2014 03 041, TA 2013 11 073, Nv 2017 08 085, 2 основных дока гинек, Печать контента170
| Cochrane Database Syst Rev
. 2015;(7):CD010555. 114. Huber A, Raio L, Alberio L, Ghezzi F, Surbek D. Recombinant human fac- tor VIIa prevents hysterectomy in severe postpartum hemorrhage: single cen- ter study. J Perinat Med . 2011;40(1):43-49. 115. Phillips L, McLintock C, Pollock W, Gatt S, et al. Australian and New Zea- land Haemostasis Registry. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemosta- sis Registry. Anesth Analg . 2009;109(6):1908-1915. 116. Lavigne-Lissalde G, Aya A, Mercier F, Roger-Christoph S, et al. Recom- binant human FVIIa for reducing the need for invasive second-line thera- pies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost . 2015;13(4):520-529. 117. Franchini M, Manzato F, Salvagno G, Lippi G. Potential role of recombi- nant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fi- brinolysis . 2007;18(7):589-593. 118. Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology . 2007;12(1):55-62. 119. Shah N, Chong S, Yusoff S, Mazlan M, et al. Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven- year single-centre experience. BMC Hematol . 2018;18:34. 120. Ahonen J. The role of recombinant activated factor VII in obstetric hemor- rhage. Curr Opin Anaesthesiol . 2012;25(3):309-314. 121. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombi- nant factor VIIa use is safe but not effective. Del Med J . 2011;83(4):109-113. 122. Dutta T, Verma S. Rational Use of Recombinant Factor VIIa in Clinical Practice. Indian J Hematol Blood Transfus . 2014;30(2):85-90. 123. Bolliger D, Mauermann E, Tanaka K. Thresholds for Perioperative Administra- tion of Hemostatic Blood Components and Coagulation Factor Concentrates: An Unmet Medical Need. J Cardiothorac Vasc Anesth . 2015;29(3):768-776. 124. Knight M, Fitzpatrick K, Kurinczuk J, Tuffnell D. Use of recombinant factor VIIa in patients with amniotic fluid embolism. Anesthesiology . 2012;117:423. 125. Neb H, Zacharowski K, Meybohm P. Strategies to reduce blood product uti- lization in obstetric practice. Curr Opin Anaesthesiol . 2017;30(3):294-299. 126. Godier A, Greinacher A, Faraoni D, Levy J, Samama M. Use of factor con- centrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. J Thromb Haemost . 2018;16(1):170-174. 127. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno G, Tar- gher G, Lippi G. The use of recombinant activated FVII in postpartum hem- orrhage. Clin Obstet Gynecol . 2010;53(1):219-227. 128. Zarychanski R, Abou-Setta A, Kanji S, Turgeon A, et al. Canadian Critical Care Trials Group. The efficacy and safety of heparin in pa- tients with sepsis: a systematic review and metaanalysis. Crit Care Med . 2015;43(3):511-518. 129. Bain E, Wilson A, Tooher R, Gates S, Davis L, Middleton P. Prophylax- is for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev . 2014;(2):CD001689. 130. Villani M, Ageno W, Grandone E, Dentali F. The prevention and treatment of venous thromboembolism in pregnancy. Expert Rev Cardiovasc Ther . 2017;15(5):397-402. 131. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of dissemi- nated intravascular coagulation (DIC) according to four DIC guidelines. жүктеу/скачать 0,76 Mb. Достарыңызбен бөлісу:
|